A significant driver of top-line growth: Harmony Biosciences Holdings Inc (HRMY)

With 0.69 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.61 million shares. The 52-week range on HRMY shows that it touched its highest point at $41.61 and its lowest point at $28.14 during that stretch. It currently has a 1-year price target of $51.67. Beta for the stock currently stands at 0.82.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HRMY was down-trending over the past week, with a drop of -5.85%, but this was down by -18.61% over a month. Three-month performance dropped to -7.61% while six-month performance fell -9.25%. The stock lost -3.25% in the past year, while it has lost -6.48% so far this year. A look at the trailing 12-month EPS for HRMY yields 2.51 with Next year EPS estimates of 3.97. For the next quarter, that number is 0.61. This implies an EPS growth rate of 18.71% for this year and 33.31% for next year.

Float and Shares Shorts:

At present, 57.14 million HRMY shares are outstanding with a float of 43.40 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HRMY since 6 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $2.54885 being high and $2.07397 being low. For HRMY, this leads to a yearly average estimate of $2.35502. Based on analyst estimates, the high estimate for the next quarter is $1.18 and the low estimate is $0.87. The average estimate for the next quarter is thus $1.02.

Summary of Insider Activity:

Insiders traded HRMY stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.